These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12128165)

  • 1. Altered drug disposition of the platelet activating factor antagonist apafant in mdr1a knockout mice.
    Leusch A; Volz A; Müller G; Wagner A; Sauer A; Greischel A; Roth W
    Eur J Pharm Sci; 2002 Aug; 16(3):119-28. PubMed ID: 12128165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain penetration of WEB 2086 (Apafant) and dantrolene in Mdr1a (P-glycoprotein) and Bcrp knockout rats.
    Fuchs H; Kishimoto W; Gansser D; Tanswell P; Ishiguro N
    Drug Metab Dispos; 2014 Oct; 42(10):1761-5. PubMed ID: 25053619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor.
    Yang JJ; Milton MN; Yu S; Liao M; Liu N; Wu JT; Gan L; Balani SK; Lee FW; Prakash S; Xia CQ
    Drug Metab Lett; 2010 Dec; 4(4):201-12. PubMed ID: 20670210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resolution of P-glycoprotein and non-P-glycoprotein effects on drug permeability using intestinal tissues from mdr1a (-/-) mice.
    Stephens RH; O'Neill CA; Bennett J; Humphrey M; Henry B; Rowland M; Warhurst G
    Br J Pharmacol; 2002 Apr; 135(8):2038-46. PubMed ID: 11959808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds.
    Dagenais C; Zong J; Ducharme J; Pollack GM
    Pharm Res; 2001 Jul; 18(7):957-63. PubMed ID: 11496955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of mdr1a expression in the brain and liver during CNS inflammation alters the in vivo disposition of digoxin.
    Goralski KB; Hartmann G; Piquette-Miller M; Renton KW
    Br J Pharmacol; 2003 May; 139(1):35-48. PubMed ID: 12746221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiologically based pharmacokinetics of digoxin in mdr1a knockout mice.
    Kawahara M; Sakata A; Miyashita T; Tamai I; Tsuji A
    J Pharm Sci; 1999 Dec; 88(12):1281-7. PubMed ID: 10585223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics, pharmacokinetics and safety profile of the new platelet-activating factor antagonist apafant in man.
    Brecht HM; Adamus WS; Heuer HO; Birke FW; Kempe ER
    Arzneimittelforschung; 1991 Jan; 41(1):51-9. PubMed ID: 1646613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antinociceptive effects of morphine-6-glucuronide in homozygous MDR1a P-glycoprotein knockout and in wildtype mice in the hotplate test.
    Lötsch J; Tegeder I; Angst MS; Geisslinger G
    Life Sci; 2000 May; 66(24):2393-403. PubMed ID: 10864101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for an active transport of morphine-6-beta-d-glucuronide but not P-glycoprotein-mediated at the blood-brain barrier.
    Bourasset F; Cisternino S; Temsamani J; Scherrmann JM
    J Neurochem; 2003 Sep; 86(6):1564-7. PubMed ID: 12950465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The anthelminthic agent albendazole does not interact with p-glycoprotein.
    Merino G; Alvarez AI; Prieto JG; Kim RB
    Drug Metab Dispos; 2002 Apr; 30(4):365-9. PubMed ID: 11901088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of difference in pulmonary absorption of digoxin, a P-glycoprotein substrate, in mdr1a-deficient and mdr1a-competent mice.
    Manford F; Riffo-Vasquez Y; Spina D; Page CP; Hutt AJ; Moore V; Johansson F; Forbes B
    J Pharm Pharmacol; 2008 Oct; 60(10):1305-10. PubMed ID: 18812023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological characterization of a receptor for platelet-activating factor on guinea pig peritoneal macrophages using [3H]apafant, a selective and competitive platelet-activating factor antagonist: evidence that the noncompetitive behavior of apafant in functional studies relates to slow kinetics of dissociation.
    Ring PC; Seldon PM; Barnes PJ; Giembycz MA
    Mol Pharmacol; 1993 Feb; 43(2):302-12. PubMed ID: 8381515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What kinds of substrates show P-glycoprotein-dependent intestinal absorption? Comparison of verapamil with vinblastine.
    Ogihara T; Kamiya M; Ozawa M; Fujita T; Yamamoto A; Yamashita S; Ohnishi S; Isomura Y
    Drug Metab Pharmacokinet; 2006 Jun; 21(3):238-44. PubMed ID: 16858128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P-gp is involved in the intestinal absorption and biliary excretion of afatinib in vitro and in rats.
    Zhang Y; Wang C; Liu Z; Meng Q; Huo X; Liu Q; Sun P; Yang X; Sun H; Ma X; Liu K
    Pharmacol Rep; 2018 Apr; 70(2):243-250. PubMed ID: 29475007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
    Zamek-Gliszczynski MJ; Bedwell DW; Bao JQ; Higgins JW
    Drug Metab Dispos; 2012 Sep; 40(9):1825-33. PubMed ID: 22711747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polysorbate 20 increases oral absorption of digoxin in wild-type Sprague Dawley rats, but not in mdr1a(-/-) Sprague Dawley rats.
    Nielsen CU; Abdulhussein AA; Colak D; Holm R
    Int J Pharm; 2016 Nov; 513(1-2):78-87. PubMed ID: 27601334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists.
    Chen C; Hanson E; Watson JW; Lee JS
    Drug Metab Dispos; 2003 Mar; 31(3):312-8. PubMed ID: 12584158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efavirenz does not interact with the ABCB1 transporter at the blood-brain barrier.
    Dirson G; Fernandez C; Hindlet P; Roux F; German-Fattal M; Gimenez F; Farinotti R
    Pharm Res; 2006 Jul; 23(7):1525-32. PubMed ID: 16779703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan.
    de Vries NA; Zhao J; Kroon E; Buckle T; Beijnen JH; van Tellingen O
    Clin Cancer Res; 2007 Nov; 13(21):6440-9. PubMed ID: 17975156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.